SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    H. Chambost, Y. Guillaume, C. Falaise, C. Roux, F. Monpoux, Actualité sur le risque de survenue d’inhibiteur à l’initiation du traitement par concentré de facteur VIII dans l’hémophilie A sévère, Revue d'Oncologie Hématologie Pédiatrique, 2015,

    CrossRef

  2. 2
    L. Miller, S. Weissmüller, E. Ringler, P. Crauwels, G. van Zandbergen, R. Seitz, Z. Waibler, Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products, Thrombosis and Haemostasis, 2015, 114, 2

    CrossRef

  3. 3
    J. Astermark, FVIII inhibitors: pathogenesis and avoidance, Blood, 2015, 125, 13, 2045

    CrossRef

  4. 4
    Brigid Unim, Maria Assunta Veneziano, Antonio Boccia, Walter Ricciardi, Giuseppe La Torre, Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand, The Scientific World Journal, 2015, 2015, 1

    CrossRef

  5. 5
    A. Nijdam, K. Kurnik, R. Liesner, R. Ljung, B. Nolan, P. Petrini, K. Fischer, How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access, Haemophilia, 2015, 21, 3
  6. 6
    Teresa Álvarez, Immaculada Soto, Jan Astermark, Non-genetic risk factors and their influence on the management of patients in the clinic, European Journal of Haematology, 2015, 94,
  7. 7
    J. Oldenburg, Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens, Blood, 2015, 125, 13, 2038

    CrossRef

  8. 8
    Paul C. Moorehead, Lisa Thibeault, Angie Tuttle, Julie Grabell, Louise Dwyre, Mariana Silva, Paula James, David Lillicrap, Rapid Acquisition of Immunologic Tolerance to Factor VIII and Disappearance of Anti-factor VIII IgG4 After Prophylactic Therapy in a Hemophilia A Patient With High-titer Factor VIII Inhibitor, Journal of Pediatric Hematology/Oncology, 2015, 37, 4, e220

    CrossRef

  9. 9
    Nuria Bermejo, Subcutaneous immunotherapy in hemophilic patients, International Forum of Allergy & Rhinology, 2015, 5, 3
  10. 10
    G. Auerswald, K. Kurnik, L. M. Aledort, H. Chehadeh, A. Loew-Baselli, K. Steinitz, A. J. Reininger, The EPIC study: a lesson to learn, Haemophilia, 2015, 21, 3
  11. 11
    Rudolf Schwarz, Rolf Ljung, Ulf Tedgård, Various regimens for prophylactic treatment of patients with haemophilia, European Journal of Haematology, 2015, 94,
  12. 12
    J. Michael Soucie, Connie H. Miller, Fiona M. Kelly, Meredith Oakley, Deborah L. Brown, Phillip Kucab, A Public Health Approach to the Prevention of Inhibitors in Hemophilia, American Journal of Preventive Medicine, 2014, 47, 5, 669

    CrossRef

  13. 13
    Margaret V Ragni, Lynn M Malec, Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance, Expert Review of Hematology, 2014, 7, 6, 747

    CrossRef

  14. You have free access to this content14
    H. M. Berg, Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors, Haemophilia, 2014, 20,
  15. 15
    Louis Aledort, Rolf Ljung, Kenneth Mann, Steven Pipe, Factor VIII therapy for hemophilia A: current and future issues, Expert Review of Hematology, 2014, 7, 3, 373

    CrossRef

  16. You have free access to this content16
    A. C. Goodeve, A. Pavlova, J. Oldenburg, Genomics of bleeding disorders, Haemophilia, 2014, 20,
  17. 17
    Susanne Fink, Steffen Kunzmann, Oliver Andres, Matthias Eyrich, Verena Wiegering, Haemophilia in extreme immature preterm infants: increased risk for intracranial haemorrhage?, Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 6, 621

    CrossRef

  18. 18
    Gili Kenet, Christoph Bidlingmaier, Nadja Bogdanova, Carmen Escuriola Ettingshausen, Neil Goldenberg, Sven Gutsche, Susan Halimeh, Susanne Holzhauer, Karin Kurnik, Verena Limperger, Ralf Junker, Ulrike Nowak-Göttl, Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A - an Israeli-German multicenter database study, Thrombosis Research, 2014, 133, 4, 544

    CrossRef

  19. 19
    J. A. Aznar, A. Moret, F. Ibáñez, C. Vila, N. Cabrera, E. Mesa, S. Bonanad, Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A, Haemophilia, 2014, 20, 5
  20. 20
    Karin Kurnik, Günter Auerswald, Wolfhart Kreuz, Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience, Thrombosis Research, 2014, 134, S27

    CrossRef

  21. You have free access to this content21
    J. Astermark, G. Dolan, T. Hilberg, V. Jiménez-Yuste, M. Laffan, R. Lassila, S. Lobet, C. Martinoli, C.-F. Perno, Managing Haemophilia for Life: 4th Haemophilia Global Summit, Haemophilia, 2014, 20,
  22. You have free access to this content22
    P. M. Mannucci, Q. Shi, S. Bonanad, R. Klamroth, Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development, Haemophilia, 2014, 20,
  23. 23
    Séverine Henrard, Brecht Devleesschauwer, Philippe Beutels, Michael Callens, Frank De Smet, Cedric Hermans, Niko Speybroeck, The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease, Orphanet Journal of Rare Diseases, 2014, 9, 1, 39

    CrossRef

  24. 24
    Bettina Kemkes-Matthes, Kathrin Heidinger, Anette Kirsch-Altena, Ronald Fischer, Blutungsneigung, CME, 2013, 10, 2, 65

    CrossRef

  25. 25
    Jerome M. Teitel, Michelle Sholzberg, Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies, Blood Reviews, 2013, 27, 2, 103

    CrossRef

  26. 26
    Samantha C. Gouw, Johanna G. van der Bom, Rolf Ljung, Carmen Escuriola, Ana R. Cid, Ségolène Claeyssens-Donadel, Christel van Geet, Gili Kenet, Anne Mäkipernaa, Angelo Claudio Molinari, Wolfgang Muntean, Rainer Kobelt, George Rivard, Elena Santagostino, Angela Thomas, H. Marijke van den Berg, Factor VIII Products and Inhibitor Development in Severe Hemophilia A, New England Journal of Medicine, 2013, 368, 3, 231

    CrossRef

  27. 27
    R. Kruse-Jarres, Inhibitors: our greatest challenge. Can we minimize the incidence?, Haemophilia, 2013, 19,
  28. 28
    S. C. Gouw, H. M. van den Berg, K. Fischer, G. Auerswald, M. Carcao, E. Chalmers, H. Chambost, K. Kurnik, R. Liesner, P. Petrini, H. Platokouki, C. Altisent, J. Oldenburg, B. Nolan, R. P. Garrido, M. E. Mancuso, A. Rafowicz, M. Williams, N. Clausen, R. A. Middelburg, R. Ljung, J. G. van der Bom, Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study, Blood, 2013, 121, 20, 4046

    CrossRef

  29. 29
    G. Grangl, S. Gallistl, B. Leschnik, W. Muntean, Port-A-Cath infection causes inhibitor recurrence after initial successful ITI, Haemophilia, 2013, 19, 3
  30. 30
    Susan Halimeh, Christoph Bidlingmaier, Christine Heller, Sven Gutsche, Susanne Holzhauer, Gili Kenet, Karin Kurnik, Daniela Manner, Alfonso Iorio, Ulrike Nowak-Göttl, Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study, BioMed Research International, 2013, 2013, 1

    CrossRef

  31. 31
    R. Schwaab, A. Pavlova, T. Albert, M. Caspers, J. Oldenburg, Significance of F8 missense mutations with respect to inhibitor formation, Thrombosis and Haemostasis, 2013, 109, 3, 464

    CrossRef

  32. 32
    J. Astermark, S. M. Donfield, E. D. Gomperts, J. Schwarz, E. D. Menius, A. Pavlova, J. Oldenburg, B. Kessing, D. M. DiMichele, A. D. Shapiro, C. A. Winkler, E. Berntorp, The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort, Blood, 2013, 121, 8, 1446

    CrossRef

  33. 33
    A. Farrugia, J. Cassar, M. C. Kimber, M. Bansal, K. Fischer, G. Auserswald, B. O'Mahony, K. Tolley, D. Noone, S. Balboni, Treatment for life for severe haemophilia A– A cost-utility model for prophylaxis vs. on-demand treatment, Haemophilia, 2013, 19, 4
  34. 34
    H. G. Watson, J. T. Wilde, G. Dolan, C. Millar, T. T. Yee, M. Makris, Update to UKHCDO guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease, Haemophilia, 2013, 19, 3
  35. 35
    N. Bermejo, C. Martín Aguilera, F. Carnicero, J. Bergua, Allergenic vaccines administration and inhibitor development in haemophilia, Haemophilia, 2012, 18, 5
  36. 36
    B. Kemkes-Matthes, K. Heidinger, A. Kirsch-Altena, R. Fischer, Blutungsneigung, Der Internist, 2012, 53, 7, 833

    CrossRef

  37. 37
    E. NANISHI, S. OHGA, T. DOI, M. ISHIMURA, K. IHARA, H. TAKADA, M. SHIMA, T. HARA, Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor, Haemophilia, 2012, 18, 3
  38. 38
    G. AUERSWALD, C. BIDLINGMAIER, K. KURNIK, Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients – long-term follow-up and continuing experience, Haemophilia, 2012, 18, 1
  39. 39
    G. Auerswald, A. Thompson, M. Recht, D. Brown, R. Liesner, N. Guzman-Becerra, J. Dyck-Jones, B. Ewenstein, B. Abbuehl, Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A, Thrombosis and Haemostasis, 2012, 107, 6, 1072

    CrossRef

  40. 40
    C. HERMANS, J. ASTERMARK, P. DE MOERLOOSE, Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?, Journal of Thrombosis and Haemostasis, 2012, 10, 10
  41. 41
    David W. Scott, Jay N. Lozier, Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation, British Journal of Haematology, 2012, 156, 3
  42. 42
    M. OLIVIERI, K. KURNIK, T. PFLUGER, C. BIDLINGMAIER, Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis, Haemophilia, 2012, 18, 3
  43. You have free access to this content43
    E. BERNTORP, S. HALIMEH, A. GRINGERI, M. MATHIAS, C. ESCURIOLA, R. PÉREZ, Management of bleeding disorders in children, Haemophilia, 2012, 18,
  44. 44
    S. RANTA, T. KALAJOKI-HELMIÖ, J. POUTTU, A. MÄKIPERNAA, MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia, Haemophilia, 2012, 18, 4
  45. You have free access to this content45
    J. ASTERMARK, Prevention and prediction of inhibitor risk, Haemophilia, 2012, 18,
  46. 46
    A. COPPOLA, A. TAGLIAFERRI, M. FRANCHINI, Searching for the role of primary prophylaxis in preventing inhibitor development in hemophilia A, Journal of Thrombosis and Haemostasis, 2012, 10, 9
  47. 47
    M. E. MANCUSO, P. M. MANNUCCI, A. ROCINO, I. GARAGIOLA, A. TAGLIAFERRI, E. SANTAGOSTINO, Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A, Journal of Thrombosis and Haemostasis, 2012, 10, 5
  48. 48
    M. V. RAGNI, P. J. FOGARTY, N. C. JOSEPHSON, A. T. NEFF, L. J. RAFFINI, C. M. KESSLER, Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres, Haemophilia, 2012, 18, 1
  49. 49
    Cedric Hermans, Hans-Hermann Brackmann, Piercarla Schinco, Günter Auerswald, The case for wider use of recombinant factor VIII concentrates, Critical Reviews in Oncology/Hematology, 2012, 83, 1, 11

    CrossRef

  50. 50
    Polly Matzinger, The evolution of the danger theory, Expert Review of Clinical Immunology, 2012, 8, 4, 311

    CrossRef

  51. 51
    Y. MESLIER, S. ANDRÉ, J. D. DIMITROV, S. DELIGNAT, J. BAYRY, S. V. KAVERI, S. LACROIX-DESMAZES, Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells, Journal of Thrombosis and Haemostasis, 2011, 9, 4
  52. 52
    R. Kruse-Jarres, Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A, Hematology, 2011, 2011, 1, 407

    CrossRef

  53. 53
    M. V. Ragni, FVIII, CD4, and liaisons dangereuses, Blood, 2011, 117, 23, 6060

    CrossRef

  54. 54
    T. STRAUSS, A. LUBETSKY, B. RAVID, D. BASHARI, J. LUBOSHITZ, S. LALEZARI, M. MISGAV, U. MARTINOWITZ, G. KENET, Recombinant factor concentrates may increase inhibitor development: a single centre cohort study, Haemophilia, 2011, 17, 4
  55. 55
    T. CELKAN, N. ÖZDEMIR, Reduced early prophylaxis of children with haemophilia in a developing country, Turkey, Haemophilia, 2011, 17, 5
  56. 56
    Rolf Ljung, Johannes Oldenburg, Günter Auerswald, Marijke van den Berg, Midori Shima, Donna DiMichele, Report of the Fifth Meeting of the International Network for Pediatric Hemophilia: a focus on prophylaxis and immune tolerance induction, International Journal of Hematology, 2011, 94, 4, 415

    CrossRef

  57. 57
    David Lillicrap, Improvements in factor concentrates, Current Opinion in Hematology, 2010, 17, 5, 393

    CrossRef

  58. 58
    Yann Meslier, Sébastien André, Maud Teyssandier, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes, Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice, Immunology, 2010, 131, 4
  59. 59
    Azza A.G. Tantawy, Molecular genetics of hemophilia A: Clinical perspectives, Egyptian Journal of Medical Human Genetics, 2010, 11, 2, 105

    CrossRef

  60. 60
    A. IORIO, S. HALIMEH, S. HOLZHAUER, N. GOLDENBERG, E. MARCHESINI, M. MARCUCCI, G. YOUNG, C. BIDLINGMAIER, L. R. BRANDAO, C. E. ETTINGSHAUSEN, A. GRINGERI, G. KENET, R. KNÖFLER, W. KREUZ, K. KURNIK, D. MANNER, E. SANTAGOSTINO, P. M. MANNUCCI, U. NOWAK-GÖTTL, Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review, Journal of Thrombosis and Haemostasis, 2010, 8, 6
  61. You have free access to this content61
    A. BATOROVA, K. A. HIGH, A. GRINGERI, Special lectures in haemophilia management, Haemophilia, 2010, 16,
  62. 62
    Alfonso Iorio, Emanuela Marchesini, Maura Marcucci, Kent Stobart, Anthony KC Chan, Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B, The Cochrane Library,
  63. 63
    Günter Auerswald, Karin Kurnik, Early Tolerization to Minimize Inhibitors in PUPs with Hemophilia A,
  64. 64
    Meera Chitlur, Jeanne Lusher, Factor VIII and IX Inhibitors in Hemophilia,
  65. 65
    Jan Astermark, Genetic and Environmental Risk Factors for Factor VIII Inhibitor Development,
  66. 66
    Johannes Oldenburg, Anna Pavlova, Genetic Basis for Inhibitor Development,
  67. 67
    Birgit M. Reipert, Christoph J. Hofbauer, Katharina N. Steinitz, Hans-Peter Schwarz, Frank M. Horling, Immunology of Inhibitor Development,
  68. 68
    Lisa N. Boggio, Mindy L. Simpson, Non-Genetic Risk Factors for Inhibitor Development,
  69. 69
    H. Marijke van den Berg, Kathelijn Fischer, Prediction of Inhibitors in Severe Hemophilia,
  70. 70
    Kathelijn Fischer, H. Marijke van den Berg, Prophylaxis,